What question did this study set out to answer?

This study aims to compare the diagnostic validity of the VISITECT CD4 lateral flow immunoassay against the Pima Analyzer.

July 26, 2026BMC Infectious DiseasesOpen Access

Evaluation of the diagnostic validity of the HIV VISITECT CD4 point-of-care rapid diagnostic test in Uganda

View Full Paper

Ask AI

Bookmark

Authors

ONOliver NakamaanyaMakerere University BBBernard BagayaMakerere University WSWilly SsengoobaMakerere University

Discussion

Member takes

Implication

Comparative cross-sectional study evaluating HIV VISITECT CD4 diagnostic validity in Uganda, suggesting reliable performance in resource-limited settings.

Key Points

This study aims to compare the diagnostic validity of the VISITECT CD4 lateral flow immunoassay against the Pima Analyzer.
Conducted a comparative cross-sectional study between June and August 2023 at three Kampala health centres.
Tested venous blood from 351 HIV-positive adults on both diagnostic platforms simultaneously.
Calculated sensitivity, specificity, PPV, NPV, and likelihood ratios using the Pima Analyzer as the reference.
VISITECT CD4 LFA sensitivity was 86.25% (95% CI: 76.73–92.93) and specificity was 90.41% (95% CI: 86.26–93.64).
The positive predictive value (PPV) was 72.63% (95% CI: 64.57–79.44), and the negative predictive value (NPV) was 95.70% (95% CI: 92.78–97.48).
Inter-rater agreement was κ = 0.957, indicating strong reliability for screening.

Cite This Study

Nakamaanya et al. (2026) studied this question.

synapsesocial.com/papers/6a65a825d3aea3239cd78904 https://doi.org/10.1186/s12879-026-14021-y

View Full Paper

Ask AI

Bookmark

Implication

Comparative cross-sectional study evaluating HIV VISITECT CD4 diagnostic validity in Uganda, suggesting reliable performance in resource-limited settings.

Evaluation of the diagnostic validity of the HIV VISITECT CD4 point-of-care rapid diagnostic test in Uganda

Discussion

Member takes

Implication

Key Points

Cite This Study

Evaluation of the diagnostic validity of the HIV VISITECT CD4 point-of-care rapid diagnostic test in Uganda

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider